MedPath

Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery

Phase 4
Terminated
Conditions
Anesthesia Recovery Period
Pain, Postoperative
Interventions
Registration Number
NCT00681174
Lead Sponsor
University of Parma
Brief Summary

The main hypothesis of this study is that preoperative administration of controlled-release (CR) oxycodone may reduce acute postoperative pain and improve time to discharge from the post-anesthesia care unit in patients undergoing video-assisted thoracoscopy for spontaneous pneumothorax.

The study drug will be compared with intravenous morphine administered 30 minutes before the end of anesthesia.

Detailed Description

Although spontaneous pneumothorax may be treated conservatively by simple observation or chest tube insertion, up to 50% of patients treated conservatively may experience recurrence in subsequent months or years.

Video-assisted thoracic surgery (VATS) is a minimally-invasive surgical approach to treat spontaneous pneumothorax and reduce the risk of recurrence. Compared to open thoracotomy, VATS may facilitate a faster recovery and lead to earlier home discharge.

Totally-intravenous anesthesia (TIVA) with propofol and remifentanil is a useful anesthetic technique for VATS, as the drugs are rapidly eliminated after the end of the procedure, leading to fast recovery from anesthesia.

One drawback of ultra-short-acting opioid remifentanil is residual hyperalgesia after the end of the infusion, particularly after VATS, which is associated with relatively short but intense pain after surgery.

Intravenous morphine, administered just before the end of anesthesia, is the typical choice for pain relief after TIVA. However, this drug may require repeated titration and may be associated with postoperative nausea and vomiting, itchiness or drowsiness in the early postoperative period.

Oxycodone, another opioid, is available in an oral controlled-release (CR) formulation which grants relatively constant plasma levels of the drug after 1 h of administration.

The investigators hypothesize that administration of CR oxycodone 20 mg 1 hour before surgery may lead to better recovery parameters in the post-anesthesia care unit, thus granting earlier discharge to the surgical ward.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • Patients scheduled for video-assisted thoracic surgery for clinical diagnosis of spontaneous pneumothorax
  • Must be able to swallow tablets 1 h before surgery
  • American Society of Anesthesiologists (ASA) physical status class I or II
Exclusion Criteria
  • Known allergy or other contraindications to study drugs
  • Acute myocardial infarction ≤6 months before enrollment
  • Serum creatinine > 2 mg/dL
  • Body mass index (BMI) > 30
  • Diagnosis of psychiatric disorders
  • Known or possible pregnancy
  • Epilepsy
  • Chronic opioid therapy or abuse

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlParavertebral blockControl intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
CROxyParavertebral blockThe intervention group will receive controlled-release oxycodone 1 h pre-operatively
CROxyRemifentanilThe intervention group will receive controlled-release oxycodone 1 h pre-operatively
ControlMorphineControl intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
ControlPropofolControl intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
ControlRemifentanilControl intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
ControlParacetamolControl intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
CROxyoxycodoneThe intervention group will receive controlled-release oxycodone 1 h pre-operatively
CROxyPropofolThe intervention group will receive controlled-release oxycodone 1 h pre-operatively
CROxyMorphineThe intervention group will receive controlled-release oxycodone 1 h pre-operatively
CROxyParacetamolThe intervention group will receive controlled-release oxycodone 1 h pre-operatively
Primary Outcome Measures
NameTimeMethod
Morphine consumption (intravenous titration in PACU + i.v. patient-controlled pump usage)48 h
Secondary Outcome Measures
NameTimeMethod
Pain intensity as measured on a visual analog scale1 h after end of anesthesia
Time to discharge from post-anesthesia care unit (Aldrete score >9)0-12 h after end of anesthesia
Nausea or vomiting48 h
Respiratory depression (SpO2 < 92% or respiratory rate <8)48 h

Trial Locations

Locations (1)

University Hospital / Azienda Ospedaliero-Universitaria

🇮🇹

Parma, PR, Italy

© Copyright 2025. All Rights Reserved by MedPath